{"task_id": "98bdc2d897e2dac9", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 237/464)", "text": "POLYPOSIS (FAP)\n(CONT\u2019D)\n226\nAntineoplastic Agents\n\n--- Page 248 ---\nChemotherapeutic\nagents\nActivitya\nMyelo.\nsupp.\nEmetogenic\nrisk\nAlopecia\nOther major toxicities\nb\nDose\nmodification\nc\nOthers\nBleomycin (IV)\nTesticular\n+\n+\n++\nPulmonary, hemorrhagic cystitis\nRenal\nMitomycin C (IV)\nGI, BR, GU\n+++\n+\n+\nPulmonary, HUS, GU irritation\nRenal\na BR breast, chorio choriocarcinoma, BMT bone marrow transplant, CML chronic myelogenous leukemia, CNS brain tumor, GI gastrointestinal, GIST gas\ntrointestinal stromal tumor, GYN gynecological, KS Kaposi sarcoma, LU lung, OV ovarian, MM multiple myeloma, NHL non Hodgkin\u2019s lymphoma, NPC naso\npharyngeal carcinoma, SA sarcoma, T testicular, TCL T cell lymphoma\nb LFT elevated liver enzymes/hepatic dysfunction, muco mucositis, photo photosensitivity\nc Dose modification may be required for dose-limiting toxicities (in bold) and also potentially renal and hepatic dysfunction\nHormonal and targeted agents\nActivity\nCytopenia\nOther major toxicities\nMonoclonal antibodies\nAlemtuzumab (Campath)\nanti CD52 (SC/IV)\nNHL, TCL\n+++\nInfusion rx\u2019n, infections (e.g. CMV, HSV, TB, fungal), pancytopenia\nBevacizumab (Avastin)\nanti VEGF (IV)\nGI\nInfusion rx\u2019n, HTN, bleed, thrombosis, GI perforations, proteinuria\nCetuximab (Erbitux)\nanti EGFR (IV)\nGI, H&N\nInfusion rx\u2019n, rash, nail/hair changes, mucositis, diarrhea,\nhypomagnesemia\nGemtuzumab (Mylotarg)\nanti CD33 (IV)\nAML\n+++\nInfusion rx\u2019n, N&V, diarrhea, fever, LFT\nPanitumumab (Vectibix)\nanti EGFR (IV)\nGI\nRash, nail/hair changes, mucositis, diarrhea, hypomagnesemia\nRituximab (Rituxan)\nanti CD20 (IV)\nNHL\n+\nInfusion rx\u2019n, infections (e.g. JC virus, CMV, PJP), cardiac arrhythmia\nTrastuzumab (Herceptin)\nanti Her2 (IV)\nBR\nInfusion rx\u2019n, cardiomyopathy\nTyrosine kinase inhibitors\nSunitinib (Sutent)\nVEGFR inhibitor (PO)\nRenal, GIST\n+\nFatigue, diarrhea, acral erythema, nail/hair changes, HTN, bleed,\nhypothyroidism, hypophosphatemia\nSorafenib (Nexavar)\nVEGFR inhibitor (PO)\nRenal, liver\n+\nFatigue, diarrhea, acral erythema, nail/hair changes, HTN, bleed,\nhypothyroidism, hypophosphatemia\nImatinib (Gleevec)\nbcr/abl, c kit inhibitor (PO)\nCML, GIST\n+\nPeriorbital edema, nausea, diarrhea, muscle cramps, bowel\nperforation, fatigue\nErlotinib (Tarceva)\nEGFR inhibitor (PO)\nLung\nRash, nail/hair changes, mucositis, diarrhea, interstitial lung dx\nGefitinib (Iressa)\nEGFR inhibitor (PO)\nLung\nRash, nail/hair changes, mucositis, diarrhea, interstitial lung dx\nLHRH agonists\nGoserelin (Zoladex) (IM)\nProstate, BR\nHot flashes, mood changes, sexual dysfunction, diarrhea, anemia,\nloss of muscle mass, osteoporosis\nLeuprolide (Lupron) (IM)\nProstate, BR\nSelective estrogen receptor modulators\nTamoxifen (Nolvadex)\nBR\nHot flashes, mood D, vaginal dryness/discharge, thromboembolism,\nhypercalcemia, endometrial cancer\nAromatase inhibitors\nAnastrozole (Arimidex)\nnon steroidal (PO)\nBR\nHot flashes, mood D, arthralgia, vaginal dryness and discharge,\nosteoporosis for all aromatase inhibitors\nLetrozole (Femara)\nnon steroidal (PO)\nBR\nExemestane (Aromasin)\nsteroidal (PO)\nBR\nOther hormonal agents\nBicalutamide (Casodex)\nanti androgen (PO)\nProstate\nHot flashes, mood changes, sexual dysfunction, diarrhea, anemia,\nloss of muscle mass, osteoporosis\nFlutamide (Eulexin)\nantiandrogen (PO)\nProstate\nFinasteride (Proscar)\na5 reductase inhibitor\nProstate\nPostural hypotension, sexual dysfunction, dizziness\nMegestrol (Megace)\nprogestin (PO)\nBR, endometrial\nVaginal bleed and irregularities, nausea, weight gai\nFulvestrant (Faslodex)\nER blocker (PO)\nBR\nHot flashes, nausea, diarrhea, back pain, pharyngitis\nOthers\nThalidomide (Thalomid)\nanti angiogenic (PO)\nMyeloma\n++\nSedation, fatigue, constipation, rash, peripheral neuropathy,\nthromboembolism\nBortezomib (Velcade)\nproteasome inhibitor (IV)\nMyeloma, NHL\n++\nGI symptoms, fatigue, cytopenia, peripheral neuropathy\nInterferon\nimmune modulatory (IV)\nMelanoma, renal\n++\nFatigue, fever, myalgia, LFT, mood changes\nTemsirolimus (Torisel)\nmTOR inhibitor (IV)\nRenal\n+\nRash, mucositis, fatigue, hyperglycemia, hypophosphatemia,\nhypertriglyceridemia\nAntineoplastic Agents (Cont\u2019d)\n227\nAntineoplastic Agents", "text_length": 4092, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 237/464)", "type": "chunk", "chunk_index": 236, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.572886", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.573637", "status": "complete", "chunks_added": 3}